ProPublica’s “Dollars for Docs” projects found a dramatic decrease in payments to doctors between 2011 and 2012 among some of the nation’s largest pharmaceutical companies. Furthermore, GlaxoSmithKline announced it would stop paying doctors to promote drugs altogether last December. This decline coincides with increased scrutiny from regulators and watchdog organizations. Per the Physician Payments Sunshine Act, all pharmaceutical and medical device companies must disclose payments to physicians. The first wave of disclosures, expected September 2014, will cover the payments made between August and December 2013. Another potential cause of this decline is the expiration of patent protection for several blockbuster drugs between 2011 and 2013. Moreover, pharmaceutical industry has changed its focus towards expensive specialty drugs, which likely require less promotion from doctors.